Source comparison
Ipamorelin for Women Over 40: Method Comparison
Ipamorelin monotherapy (200–250 mcg daily) Selective GHS-R1a activation; triggers pulsatile GH release without cortisol or prolactin elevation Noticeable sleep and recovery improvements within 2–3 weeks; body composition changes visible at 6–8 weeks Low. Maint
This comparison does not assign a generated winner or score.
- Ipamorelin monotherapy (200–250 mcg daily)
- Selective GHS-R1a activation; triggers pulsatile GH release without cortisol or prolactin elevation
- Noticeable sleep and recovery improvements within 2–3 weeks; body composition changes visible at 6–8 weeks
- Low. Maintains sensitivity across 8–12 week cycles with proper dosing intervals
- Best first option for women new to peptides; lowest side effect profile and highest long-term tolerability
- Ipamorelin + CJC-1295 stack
- Ipamorelin triggers GH pulse; CJC-1295 extends pulse duration by inhibiting degradation
- Faster body composition changes (4–6 weeks); more pronounced recovery benefits
- Moderate. Requires structured off-cycles (4 weeks on, 2 weeks off) to prevent downregulation
- More effective for measurable outcomes but demands stricter protocol adherence and cycle structure
- GHRP-6 or GHRP-2 monotherapy
- Broad-spectrum ghrelin receptor activation; higher peak GH but also elevates cortisol and appetite
- Similar GH elevation to ipamorelin but with increased hunger and potential stress hormone disruption
- Moderate to high. Cortisol elevation can compound existing metabolic stress in perimenopausal women
- Not recommended as first-line; use only if ipamorelin proves insufficient after 8-week trial
- Exogenous GH replacement
- Direct GH administration; bypasses endogenous production entirely
- Immediate systemic effects; fastest body composition changes (2–4 weeks)
- N/A. Shuts down natural GH production; requires medical supervision and costly monitoring
- Reserved for diagnosed GH deficiency; inappropriate for age-related decline without clinical diagnosis